Clinical trials: Non-squamous NSCLC
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04344795
- Testing
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 89 people
- Sponsor
- Tempest Therapeutics
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer.
- Trial name
- DL03 (NCT04686305)
- Testing
- T-DXd, Durvalumab, Cisplatin
- Where
- 91 sites in United States, Australia and 17 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Non-squamous, Non-Small Cell Lung Cancer
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer.
- Trial name
- LuTK03 (NCT07660094)
- Testing
- Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Candel Therapeutics, Inc.
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
The LUME-Lung3 study is in 2 parts: Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
- Trial name
- NCT01346540
- Testing
- BIBF 1120
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Non-Squamous Non-small Cell Lung Cancer
Phase III Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT06396065
- Testing
- AK112 Injection
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 420 people
- Sponsor
- Summit Therapeutics
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV…
- Trial name
- NCT01828099
- Testing
- Ceritinib, Pemetrexed, Cisplatin
- Where
- 167 sites in Argentina, Australia and 27 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
- Trial name
- NCT00252382
- Testing
- SNS-595 Injection
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sunesis Pharmaceuticals
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Lung Cancer, Non-Small Cell
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis.
- Trial name
- NCT04581824
- Testing
- Dostarlimab, Pembrolizumab, Chemotherapy
- Where
- 58 sites in United States, Argentina and 10 more
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Solid Tumors
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC), platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer (TNBC).
- Trial name
- NCT01930292
- Testing
- Part A: Debio 1143, Paclitaxel, Carboplatin
- Where
- 4 sites in France
- Volunteers
- 31 people
- Sponsor
- Debiopharm International SA
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice.
- Trial name
- NCT01893268
- Where
- 88 sites in France
- Volunteers
- 279 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are…
- Trial name
- NCT05537740
- Testing
- BAY3375968, Pembrolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 129 people
- Sponsor
- Bayer
Non Squamous Non Small Cell Lung Cancer
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with…
- Trial name
- NCT06687369
- Testing
- MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda®
- Where
- 173 sites in Armenia, Bosnia and Herzegovina and 22 more
- Volunteers
- 726 people
- Sponsor
- mAbxience Research S.L.
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Efficacy
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
In this randomized, double-blind, multicenter, phase III similarity study, treatment naive, EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (ns-NSCLC) patients were enrolled…
- Trial name
- NCT05427305
- Testing
- TAB008, Bevacizumab
- Where
- China
- Volunteers
- 549 people
- Sponsor
- BioDlink Biopharm Co., Ltd.